All-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells

Clinical Cancer Research

Volumn 3, Issue 11, 1997, Pages 2033-2038

  Aebi, Stefan ^a   Kröning, Relef ^b   Cenni, Bruno ^b   Sharma, Ashima ^b   Fink, Daniel ^b   Los, Gerrit ^b   Weisman, Robert ^b   Howell, Stephen B ^b   Christen, Randolph D ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GLUTATHIONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RETINOIC ACID;

APOPTOSIS; ARTICLE; CELL DENSITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KINETICS; OVARIAN NEOPLASMS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 1842295208     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Barry, M. A., Behnke, C. A., and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol., 40: 2353-2362, 1990.
2. Havrilesky, L. J., Elbendary, A., Hurteau, J. A., Whitaker, R. S., Rodriguez, G. C., and Berchuck, A. Chemotherapy-induced apoptosis in epithehal ovarian cancers. Obstet. Gynecol. 85: 1007-1010, 1995.
3. Eliopoulos, A. G., Kerr, D. J., Herod, J., Hodgkins, L., Krajewski, S., Reed, J. C., and Young, L. S. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11: 1217-1228, 1995.
4. Marshall, J. L., and Andrews, P. A. Preclinical and clinical experience with cisplatin resistance. Hematol. Oncol. Clin. N. Am., 9: 415-429, 1995.
5. Golstein, P. Controlling cell death. Science (Washington DC), 275: 1081-1082, 1997.
6. Blaner, W. S., and Olson, J. A. Retinol and retinoic acid metabolism. In: M. B. Sporn, A. B. Roberts, and D. S. Goodman (eds.), The Retinoids. Biology, Chemistry, and Medicine., Ed. 2, pp. 229-255. New York: Raven Press, 1994.
7. Mangelsdorf, D. J., Umesono, K., and Evans, R. M. The retinoid receptors. In: M. B. Sporn, A. B. Roberts, and D. S. Goodman (eds.), The Retinoids. Biology, Chemistry, and Medicine., Ed. 2, pp. 319-349. New York: Raven Press, 1994.
8. Brooks, S. E., Timmerman, J., Lau, C. C., Tsao, S. W., Knapp, R. C., and Sheets, E. E. Effect of differentiation agents on expression of CA 125, alkaline phosphatase, and cytokeratins in human ovarian adenocarcinoma cells (OVCA 433). Gynecol. Oncol., 42: 265-272, 1991.
9. Caliaro, M. J., Marmouget, C., Guichard, S., Mazars, P., Valette, A., Moisand, A., Bugat, R., and Jozan, S. Response of four human ovarian carcinoma cell lines to all-trans retinoic acid: relationship with induction of differentiation and retinoic acid receptor expression. Int. J. Cancer, 56: 743-748, 1994.
10. Lotan, R. Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res., 54: 1987s-1990s, 1994.
11. Krupitza, G., Hulla, W., Harant, H., Dittrich, E., Kallay, E., Huber, H., Grunt, T., and Dittrich, C. Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. Int. J. Cancer, 61: 649-657, 1995.
12. Sacks, P. G., Harris, D., and Chou, T. C. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int. J. Cancer, 61: 409-415, 1995.
13. Caliaro, M. J., Vitaux, P., Lafon, C., Lochon, I., Nehme, A., Valette, A., Cancal, P., Bugat, R., and Jozan, S. Multifactorial mechanisms for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br. J. Cancer, 75: 333-340, 1997.
14. Shalinsky, D. R., Bischoff, E. D., Gregory, M. L., Lamph, W. W., Heyman, R. A., Hayes, S., Thomazy, V., and Davies, P. J. A. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin. Cancer Res., 2: 511-520, 1996.
15. Disaia, P. J., Sinkovics, J. G., Rutledge, F. N., and Smith, J. P. Cell-mediated immunity to human malignant cells. Am. J. Obstet. Gynecol., 114: 979-989, 1972.
16. Andrews, P. A., Murphy, M. P., and Howell, S. B. Differential potentiation of alkylating and platinating agent toxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res., 45: 6250-6253, 1985.
17. Grenman, R., Burk, D., Virolainen, E., Buick, R. N., Church, J., Schwartz, D. R., and Carey, T. E. Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int. J. Cancer, 44: 131-136, 1989.
18. Nakata, B., Barton, R. M., Robbins, K. T., Howell, S. B., and Los, G. Association between hsp60 mRNA levels and cisplatin resistance in human head and neck cancer cell lines. Int. J. Oncol., 5: 1425-1432, 1994.
19. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
20. Eastman, A. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum. Biochemistry, 22: 3927-3933, 1983.
21. Jekunen, A. P., Hom, D. K., Alcaraz, J. E., Eastman, A., and Howell, S. B. Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells. Cancer Res., 54: 2680-2687, 1994.
22. Jekunen, A. P., Christen, R. D., Shalinsky, D. R., and Howell, S. B. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br. J. Cancer, 69: 299-306, 1994.
23. Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E., and Poirier, G. G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res., 53: 3976-3985, 1993.
24. McGahon, A. J., Martin, S. J., Bissonnette, R. P., Mahboubi, A., Shi, Y., Mogil, R. J., Nishioka, W. K., and Green, D. R. The end of the (cell) line: methods for the study of apoptosis in vitro. In: L. M. Schwartz and B. A. Osborne (eds.), Cell Death, Vol. 46, pp. 153-185. San Diego: Academic Press, 1995.
25. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T. T., Yu, V. L., and Miller, D. K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature (Lond.), 376: 37-43, 1995.
26. Oltvai, Z. N., and Korsmeyer, S. J. Checkpoint of dueling dimers foil death wishes. Cell, 79: 189-192, 1994.
27. Wouda, S., Timmer, B., Mulder, N. H., Dam, A., Koudstaal, J., and Oosterhuis, J. W. Retinoic acid and cis-diamminedichloroplatinum in the treatment of murine teratocarcinomas in vivo in a nullipotent model. J. Immunother., 13: 261-266, 1993.
28. Lucek, R. W., and Colburn, W. A. Clinical pharmacokinetics of the retinoids. Clin. Pharmacokinet., 10: 38-62, 1985.
29. Vermorken, J. B., van der Vijgh, W. J., Klein, I., Gall, H. E., van Groeningen C. J., Hart, G. A., and Pinedo, H. M. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin. Pharmacol. Ther., 39: 136-144, 1986.
30. Reed, J. C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol., 7: 541-546, 1995.
31. Hu, Z. B., Minden, M. D., and McCulloch, E. A. Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells. Leukemia (Baltimore), 9: 1667-1673, 1995.
32. Agarwal, N., and Mehta, K. Possible involvement of Bcl-2 pathway in retinoid X receptor alpha-induced apoptosis of HL-60 cells. Biochem. Biophys. Res. Commun., 230: 251-253, 1997.
33. Jozan, S., Lafon, C., Mathieu, C., Caliaro, M. J., Barboule, N., Bugat, R., and Valette, A. Enhancement of cisplatin cytotoxicity by all-trans retinoic acid in a human ovarian carcinoma cell line (OVCCR1) is characterized by apoptosis. Proc. Am. Assoc. Cancer Res., 37: 414, 1996.
34. Kolla, V., Lindner, D. J., Xiao, W., Borden, E. C., and Kalvakolanu, D. V. Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J. Biol. Chem., 271: 10508-10514, 1996.
35. Weihua, X., Kolla, V., and Kalvakolanu, D. V. Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J. Biol. Chem., 272: 9742-9748, 1997.
36. Gianni, M., Terao, M., Fortino, I., LiCalzi, M., Viggiano, V., Barbui, T., Rambaldi, A., and Garattini, E. Stal1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood, 89: 1001-1012, 1997.
37. Davies, P. J. A., and Lippman, S. M. Biologic basis of retinoid pharmacology: implications for cancer prevention and therapy. Adv. Oncol., 12: 2-10, 1996.
38. Treat, J., Friedland, D., Luginbuhl, W., Meehan, L., Gorman, G., Miller, W., Jr., Bavaria, J., and Kaiser, L. Phase II trial of all-trans retinoic acid in metastatic non-small cell lung cancer. Cancer Invest., 14: 415-420, 1996.
39. Winer, E., Sutton, L., Petros, W., Havlin, K., King, S., and Iglehart, J. Phase II trial of all-trans retinoic acid (TRA) in patients (PTS) with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 13: 61, 1994.
40. Yung, W. K. A., Scott, C., Fischbach, A. J., Phuphanich, S., and Langer, C. J. all-trans retinoic acid: a Phase II radiation therapy oncology group study (RTOG-9113) in patients with recurrent malignant astrocytoma. Proc. Am. Soc. Clin. Oncol., 13: 176, 1994.